A2 Katsausartikkeli tieteellisessä aikausilehdessä
Therapeutic targets for enterovirus infections (2020)


Laajala, M., Reshamwala, D., & Marjomäki, V. (2020). Therapeutic targets for enterovirus infections. Expert Opinion On Therapeutic Targets, 24(8), 745-757. https://doi.org/10.1080/14728222.2020.1784141


JYU-tekijät tai -toimittajat


Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajatLaajala, Mira; Reshamwala, Dhanik; Marjomäki, Varpu

Lehti tai sarjaExpert Opinion On Therapeutic Targets

ISSN1472-8222

eISSN1744-7631

Julkaisuvuosi2020

Volyymi24

Lehden numero8

Artikkelin sivunumerot745-757

KustantajaTaylor & Francis

JulkaisumaaBritannia

Julkaisun kielienglanti

DOIhttps://doi.org/10.1080/14728222.2020.1784141

Julkaisun avoin saatavuusEi avoin

Julkaisukanavan avoin saatavuus


Tiivistelmä

Introduction
Enteroviruses are among the most common viruses causing a huge number of acute and chronic infections leading to high economic costs. Novel non-toxic antivirals that reduce the virus load in acutely infected individuals and from various surfaces are needed to efficiently combat these viruses.

Areas covered
This review summarizes the recent findings of compounds and tools targeting the enteroviruses and host cell molecules that are crucial for virus infection. In addition, the review states the modern methods to find new targets and tools that help to understand the mechanisms of action.

Expert opinion
High throughput molecular screens have revealed important aspects of virus life cycle in host cells and, concomitantly, some of the targets and compounds found serve as potential anti-virals combatting enterovirus infections. The risk of resistance development found for direct capsid binders lowers their usefulness, but combining them with compounds targeting evolutionarily conserved processes such as replication/translation makes them potentially a valid therapy for the future. Further automation and access to structural molecular tools such as cryo-EM and further development of e.g. docking and simulation of large virus particles requiring heavy computation will contribute to better understanding of molecular mechanisms of action of future antivirals.


YSO-asiasanatviruksetenteroviruksetinfektiotinfektiotauditlääkkeetlääkehoitoresistanssiisäntäsolut

Vapaat asiasanatantiviraaliset lääkkeet


Liittyvät organisaatiot


Hankkeet, joissa julkaisu on tehty


OKM-raportointiKyllä

Raportointivuosi2020

JUFO-taso1


Viimeisin päivitys 2024-03-04 klo 22:06